Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the α‐glucosidase inhibitor acarbose
Authors:
- 25 January 2005
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 19 (6) , 1-13
Abstract
Protective effects of the α‐glucosidase inhibitor acarbose have been reported for various diabetic complications. In the STOP‐NIDDM study, even patients without overt diabetes, but with impaired glucose tolerance, had a reduction in cardiovascular events when treated with acarbose. Therefore, we investigated the effect of repetitive postprandial hyperglycemia on the cardiac ischemia/reperfusion injury in vivo. Mice were treated daily by single applications of placebo, sucrose (4 g/kg body weight), or sucrose + acarbose (10 mg/kg body weight) by gavage for 7 days. Acarbose treatment significantly reduced the sucrose‐induced increase in plasma glucose concentration. Subsequently, animals underwent 30 min of ischemia by coronary artery ligation and 24 h of reperfusion in vivo. In the sucrose group, ischemia/reperfusion damage was significantly increased (infarct/area at risk, placebo vs. sucrose, 38.8±7.5% vs. 62.2±4.8%, P <0.05). This was prevented by acarbose treatment (infarct/area at risk 30.7±7.2%). While myocardial inflammation was similar in all groups, oxidative stress as indicated by a significant increase in lipid peroxides was enhanced in the sucrose, but not in the sucrose + acarbose group. In summary, repetitive postprandial hyperglycemia increases ischemia/reperfusion damage. This effect can be prevented by treatment with the α‐glucosidase inhibitor acarbose.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (1377/4-3)
This publication has 30 references indexed in Scilit:
- Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient MiceCirculation, 2004
- Peroxisome proliferator activated‐receptor agonism and left ventricular remodeling in mice with chronic myocardial infarctionBritish Journal of Pharmacology, 2004
- Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose ToleranceJAMA, 2003
- Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failureCardiovascular Research, 2003
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialThe Lancet, 2002
- Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardiumJournal of Clinical Investigation, 1999
- Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.Diabetes Care, 1999
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention TrialDiabetes Care, 1993
- Glucosidase inhibitionThe Science of Nature, 1977